Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | FPR2 | P25090 | 4/20 | 0.63 |
| ▸ | CASR | P41180 | 1/20 | 0.63 |
| ▸ | CNR1 | P21554 | 1/20 | 0.63 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.61 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18856931 | 0.94 | FPR2 (0.61) | SMN1; SMN2NPC1RAB9AFPR2CASR | |
| SCHEMBL10598972 | 0.90 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9AFPR2CASR | |
| SCHEMBL19173201 | 0.88 | RXFP1 (0.72) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL20708118 | 0.87 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AFPR2CASR | |
| SCHEMBL9435964 | 0.86 | RAB9A (0.72) | SMN1; SMN2NPC1RAB9AFPR2CASR | |
| SCHEMBL3146895 | 0.85 | FPR2 (0.66) | SMN1; SMN2NPC1RAB9AFPR2CASR | |
| SCHEMBL1912325 | 0.85 | CNR1 (0.67) | SMN1; SMN2NPC1RAB9AFPR2CASR | |
| SCHEMBL16562079 | 0.84 | FPR2 (0.86) | SMN1; SMN2NPC1RAB9AFPR2CNR1 | |
| SCHEMBL22170205 | 0.83 | CASR (0.71) | SMN1; SMN2NPC1RAB9AFPR2CASR | |
| SCHEMBL11092496 | 0.82 | RAB9A (1.00) | SMN1; SMN2NPC1RAB9ASAE1UBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | disclosed |
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | disclosed |
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-5719279-A | CHOLINOMIMETICS | BOEHRINGER INGELHEIM KG (DE) | 1998-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | HLA-DRB1, MUC1, ASGR1 | SMN1; SMN2 4758/4885NPC1 804/4885RAB9A 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.